225 related articles for article (PubMed ID: 27661208)
1. Leptomeningeal metastases of solid cancer.
Le Rhun E; Galanis E
Curr Opin Neurol; 2016 Dec; 29(6):797-805. PubMed ID: 27661208
[TBL] [Abstract][Full Text] [Related]
2. Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions.
Lee DW; Lee KH; Kim JW; Keam B
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399673
[TBL] [Abstract][Full Text] [Related]
3. An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Ghosn M; Assi T; El Rassy E; Moussa T; Kattan J
Bull Cancer; 2017 Apr; 104(4):385-387. PubMed ID: 28131317
[No Abstract] [Full Text] [Related]
4. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
Tamiya A; Tamiya M; Nishihara T; Shiroyama T; Nakao K; Tsuji T; Takeuchi N; Isa SI; Omachi N; Okamoto N; Suzuki H; Okishio K; Iwazaki A; Imai K; Hirashima T; Atagi S
Anticancer Res; 2017 Aug; 37(8):4177-4182. PubMed ID: 28739703
[TBL] [Abstract][Full Text] [Related]
5. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.
Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC
J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749
[TBL] [Abstract][Full Text] [Related]
6. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
Kuiper JL; Smit EF
Lung Cancer; 2013 Apr; 80(1):102-5. PubMed ID: 23375403
[TBL] [Abstract][Full Text] [Related]
7. Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature.
How J; Mann J; Laczniak AN; Baggstrom MQ
Clin Lung Cancer; 2017 Jul; 18(4):354-363. PubMed ID: 28245967
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.
Lombardi G; Di Stefano AL; Farina P; Zagonel V; Tabouret E
Cancer Treat Rev; 2014 Sep; 40(8):951-9. PubMed ID: 24909312
[TBL] [Abstract][Full Text] [Related]
9. Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR-mutant non-small cell lung cancer.
Mizusaki S; Otsubo K; Ninomiya T; Arimura H; Tsuchiya-Kawano Y; Inoue K
Thorac Cancer; 2021 Jan; 12(1):114-116. PubMed ID: 33112047
[TBL] [Abstract][Full Text] [Related]
10. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
[No Abstract] [Full Text] [Related]
11. Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis.
Kamath SD; Kumthekar PU; Kruser TJ; Mohindra NA
Oncologist; 2018 Dec; 23(12):e159-e161. PubMed ID: 30072392
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
Sakata Y; Kawamura K; Shingu N; Ichikado K
Lung Cancer; 2016 Sep; 99():120-2. PubMed ID: 27565925
[TBL] [Abstract][Full Text] [Related]
14. Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations.
Li YS; Jiang BY; Yang JJ; Tu HY; Zhou Q; Guo WB; Yan HH; Wu YL
J Thorac Oncol; 2016 Nov; 11(11):1962-1969. PubMed ID: 27539328
[TBL] [Abstract][Full Text] [Related]
15. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
16. Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
Kawaguchi Y; Hanaoka J; Hayashi H; Mizusaki N; Iihara H; Itoh Y; Sugiyama T
Chemotherapy; 2017; 62(3):147-150. PubMed ID: 28030859
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027
[TBL] [Abstract][Full Text] [Related]
18. Intraventricular chemotherapy for leptomeningeal carcinomatosis from lung cancer: a feasible and beneficial treatment option?
Christoph DC; Reckamp KL
J Thorac Oncol; 2013 May; 8(5):523-4. PubMed ID: 23584292
[No Abstract] [Full Text] [Related]
19. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
20. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
